ALZAMEND NEURO, INC. Weighted Average Number of Shares Outstanding, Basic and Diluted
ALZAMEND NEURO, INC. (ALZN) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 93.46 million shares for the 3-month period ending 2021-10-31, per its 10-Q filed 2021-12-13.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2021-12-13
- ALZAMEND NEURO, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-10-31 was 93.46M shares, a 29.33% increase year-over-year.
- ALZAMEND NEURO, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-07-31 was 84.59M shares, a 17.06% increase year-over-year.
- ALZAMEND NEURO, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-10-31 was 72.26M shares.
- ALZAMEND NEURO, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-07-31 was 72.26M shares.
- ALZAMEND NEURO, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2021 was 72.65M shares, a 1.96% increase from fiscal 2020.
- ALZAMEND NEURO, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 71.25M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|
| 2021-10-31 | 93.46M shares 10-Q · filed 2021-12-13 | 88.15M shares 10-Q · filed 2021-12-13 | |
| 2021-07-31 | 84.59M shares 10-Q · filed 2021-09-13 | ||
| 2021-04-30 | 72.65M shares 10-K · filed 2021-07-29 | ||
| 2020-10-31 | 72.26M shares 10-Q · filed 2021-12-13 | 72.26M shares 10-Q · filed 2021-12-13 | |
| 2020-07-31 | 72.26M shares 10-Q · filed 2021-09-13 | ||
| 2020-04-30 | 71.25M shares 10-K · filed 2021-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B |